Loading patent…
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsDipali Deshpande, Darya Burakov, Gang Chen, James Fandl
Estimating the term…
The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on GPT genes of mammalian origin. The invention includes methods that facilitate selectivity and enhanced expression copies as well as protein yield of recombinant proteins in mammalian cells, and methods of using GPT expression systems.
-29. (canceled)
A method of employing tunicamycin (Tn) as a selection marker in mammalian cell culture, comprising
Dependencies are inferred from the claim text.